Congenital Contractures NGS Panel

Test Information

This panel of 57 genes is intended for patients with a diagnosis of Congenital Contractures and is performed by Next Generation Sequencing.This molecular test is useful to confirm the diagnosis and to identify the disease causing mutations within a family to allow for carrier testing and prenatal diagnosis.

Turnaround Time

8 weeks

CPT Code(s)

81443

Cost

$3,000

Genes

  • ACTA1
  • ADCY6
  • ADGRG6
  • ALG2
  • ANTXR2
  • CHAT
  • CHMP1A
  • CHRNA1
  • CHRNB1
  • CHRND
  • CHRNE
  • CHRNG
  • CHST14
  • CNTN1
  • CNTNAP1
  • COL3A1
  • DNM2
  • DOK7
  • ECEL1
  • ERBB3
  • ERCC6
  • FBN1
  • FBN2
  • FKBP10
  • GLDN
  • GLE1
  • KLHL41
  • LMNA
  • MUSK
  • MYBPC1
  • MYH2
  • MYH3
  • MYH8
  • NALCN
  • NEB
  • NEK9
  • PIEZO2
  • PIP5K1C
  • PITX1
  • PLOD2
  • PLOD3
  • PSMB8
  • RAPSN
  • RIPK4
  • SCARF2
  • SKI
  • SLC18A3
  • SLC39A13
  • SLC5A7
  • TNNI2
  • TNNT3
  • TPM2
  • TPM3
  • UBA1
  • ZBTB42
  • ZC4H2
  • ZMPSTE24

Clinical Information

Congenital contractures are defined by constrictions or rigidity of connective tissues including muscles, ligaments, and tendons resulting in decreased range of motion and stiffness. Contractures occur in numerous genetic disorders, but the features of these syndromes vary greatly and can affect a wide variety of body systems. Treatment is symptomatic and involves physical and occupational therapy, as well as surgical correction when necessary. While over half of these conditions are inherited in an autosomal recessive manner, many phenotypes caused by changes in the same gene have been reported with either dominant or recessive inheritance. In addition, two conditions demonstrate X-linked recessive inheritance.

Methodology

Next Generation Sequencing

Detection

The current design of this panel covers all genes and the flanking intronic sequences. This method allows for analysis of greater than 98% of the targeted sequence for the detection of nucleotide substitutions and small deletions and duplications. Large deletions and duplications will not be detected by this panel. Mutations and variants identified on the panel are confirmed with Sanger sequencing. All novel and apparently pathogenic changes are reported when found within the coding region as well as within 10 basepairs of each intron/exon boundary for each gene. Promoter and 3' untranslated sequences are not included in the current analysis. It should be noted that the current protocol is not specifically designed to detect copy number alterations and single exon deletions may require additional follow-up to determine whether or not they represent technical artifacts. We recommend further array-based testing to more accurately address the concerns of dosage alterations. The Cytogenetic Laboratory at GGC offers a high resolution microarray to complement the sequencing panel. The GGC Diagnostic Laboratory Directors are available for further consultation regarding the limitations of the NGS and array testing procedures.

Specimen Requirements

The preferred sample type is 3-5 ml of peripheral blood collected in an EDTA (purple top) tube. Extracted DNA and saliva are also accepted for this test. Saliva samples must be submitted in an approved saliva kit. Contact the lab to receive a saliva kit or to have one sent to your patient.

Transport Instructions

The specimen should be kept at room temperature and delivered via overnight shipping. If shipment is delayed by one or two days, the specimen should be refrigerated and shipped at room temperature. Do not freeze the specimen. Samples collected on Friday can be safely designated for Monday delivery.

Prenatal Testing Information

If the pathogenic mutation(s) are identified in an affected individual using this panel, prenatal diagnosis is available for future pregnancies. Sanger sequencing will be used for prenatal diagnosis when there is a known familial mutation. Prenatal diagnosis can also be requested when there are clincial features and ultrasound findings suggestive of a diagnosis. Additional fees for cell culture and maternal cell contamination may apply. Maternal cell contamination studies are required for all prenatal molecular tests. Contact the laboratory prior to sending a prenatal specimen.

Have Questions? Need Support?

Call our laboratory at 1-800-473-9411 or contact one of our Laboratory Genetic Counselors for assistance.
Robin Fletcher, MS, CGC
Falecia Thomas, MS, CGC
Alex Finley, MS, CGC

Meet Reggie Roper

Reggie has been part of the GGC family for over 18 years. He has short stature, webbing of his hands, pulmonary stenosis, seizures and hydrocephalus along with developmental delay. He carried an initial diagnosis of cardiofaciocutaneous (CFC) syndrome; however, as genetic testing advanced, GGC made the diagnosis of Noon...

In The News